Clock-stops delaying Danes’ access to innovative medicines

As many as four out of 10 assessments of new drugs carried out by the Danish Medicines Council had the process stopped midway in 2025, according to pharma industry group Lif.

This is a significant increase compared to 2024, when fewer than one in four assessments experienced a so-called clock-stop. It also takes an average of more than a month longer to get the case restarted than last year. 

Lif has expressed concern at this development, which is shown by its Medicines Council Tracker.